IBA may develop bioassays
IBA (Ion Beam Applications) reported that it has received an offer from a leading financial consortium to develop its bioassays business.

If IBA’s board of directors approves the deal, the financier would provide funding for bioassays project, plus a structure appropriate to IBA’s growth potential and development strategy, according to IBA.

Under the terms of the offer, the Louvain-la-Neuve, Belgium-based IBA would remain a player in bioassays, with a 40 percent stake in its capital.